title: The application of the National Institute of Clinical Excellence guidelines for treatment of metastatic renal cell carcinoma in the United Kingdom: friend or foe?
authors.affiliation: St Bartholomew's Hospital, London, UK. Thomas.Powles@bartsandthelondon.nhs.uk
authors.forename: Thomas
authors.initials: T
authors.lastname: Powles
authors.forename: Rob
authors.initials: R
authors.lastname: Jones
authors.forename: Simon
authors.initials: S
authors.lastname: Chowdhury
authors.forename: Jonathan
authors.initials: J
authors.lastname: Shamash
authors.forename: Mark
authors.initials: M
authors.lastname: Mantle
authors.forename: Louise
authors.initials: L
authors.lastname: Lim
authors.forename: Tom
authors.initials: T
authors.lastname: Hutson
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002292:Carcinoma, Renal Cell / Q000188:drug therapy* / Q000556:secondary; D017277:Drug Approval; D000068338:Everolimus; D006801:Humans; D007211:Indoles / Q000627:therapeutic use*; D007680:Kidney Neoplasms / Q000188:drug therapy*; D017410:Practice Guidelines as Topic; D011758:Pyrroles / Q000627:therapeutic use*; D020123:Sirolimus / Q000031:analogs & derivatives / Q000627:therapeutic use; D000077210:Sunitinib; D006113:United Kingdom
chemical_list: D000970:Antineoplastic Agents; D007211:Indoles; D011758:Pyrroles; D000068338:Everolimus; D000077210:Sunitinib; D020123:Sirolimus